PubRank

Scott D Berkowitz

Author PubWeight™ 83.07‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 28.99
2 Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012 11.86
3 Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010 9.92
4 Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009 6.83
5 Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003 3.96
6 Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013 2.21
7 Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013 2.17
8 Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005 1.87
9 Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am 2005 1.59
10 Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2010 1.39
11 Complication rates after hip or knee arthroplasty in morbidly obese patients. Clin Orthop Relat Res 2013 1.37
12 The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003 1.33
13 Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011 1.10
14 Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am Heart J 2002 1.07
15 Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002 1.00
16 Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke 2014 0.94
17 Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013 0.93
18 The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002 0.87
19 Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. Int J Cardiol 2013 0.87
20 Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci 2013 0.86
21 Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013 0.86
22 Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014 0.85
23 End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes 2013 0.83
24 The discovery and development of rivaroxaban. Ann N Y Acad Sci 2011 0.80
25 Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. Am Heart J 2002 0.77
26 Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. Eur Heart J 2013 0.76
27 The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol 2013 0.75